<DOC>
	<DOCNO>NCT00726856</DOCNO>
	<brief_summary>This retrospective study evaluate effectiveness safety ezetimibe plus statin ezetimibe plus fenofibrate dyslipidemic patient treat dual inhibition lipid lower regimens part normal standard care . This study assess percentage patient achieve LDL-C target goal also evaluate patient compliance treatment .</brief_summary>
	<brief_title>Retrospective Survey Evaluating Effectiveness Safety Dual Inhibition Lipid-lowering Treatment Dyslipidemia ( Study P05171 ) ( COMPLETED )</brief_title>
	<detailed_description>Retrospective medical chart review</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patient &gt; 20 year &lt; 75 year age index date* Patient diagnose dyslipidemia respond adequately base NCEP ATP III target previous lipid lower treatment , receive dual inhibition therapy , ezetimibe plus statin , ezetimibe plus fenofibrate ezetimibe alone , least 3 month Patient least one Total Cholesterol LDLC measurement baseline 3 month initiate dual inhibition therapy . Patient follow record document chart data collection period : Medical history co morbidity ( available ) Total Cholesterol LDLC . test result initiate dual inhibition therapy Prescription information lipidlowering dual inhibition regimen NOTE : * Index date : date initiate dual inhibition therapy Patients meet inclusion criterion exclude survey . Patients enrol clinical trial observe specific study procedure deviate normal practice include study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>